1Ginsburg GS, McCarthy JJ. Personalized medicine:revolutionizing drug discovery and patient care[ J ]. Trends - Biotechnol,2001,19 (12) :491 -496.
2Pusztai L, Ayers M Stec J, Hortobagyi GN. Clinical application of cDNA microarrays in oneology [ J ]. Oncologist,2003,8 ( 3 ) : 252 - 258.
3Macgregor PF. Gene expression in cancer: the application of microarrays [ J ]. Expert Rev Mol Diagn,2003,3 ( 2 ) : 185 - 200.
4Rosell R. Pharmacogenomics comes of age in selecting patients for lung cancer treatment. American Society of Clinical Oncology[ C ]. U. S. A :42 nd Annual Meeting, 2006 : 425 - 430.
5Mizuho Tanabe, Hiroto Izumi, Tomoko Ise, et al. Activating transcription factor 4 increases the eisplatin resistance of human cancer cell lines[ J]. Cancer Res,2003 ,63 :8592 -8595.
6Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non - small - cell lung cancer patients treated with cisplatin combination chemotherapy [J]. Lung Cancer,2004,44(3):311 -316.
7Gurubhagavatula S,Liu G,Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non - small - cell lung cancer patients treated with platinum chemotherapy[ J]. J Clin Oncol,2004,22 ( 13 ) :2594 - 2601.
8Weaver DA, Crawford EL, Warner KA, et al. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non - small cell lung cancer cell lines [ J ]. Mol Cancer,2005,4( 1 ) : 18.
9Lu C,Spitz MR, Zhao H, et al. Association between glutathione S - transferase polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma [ J ]. Cancer, 2006,106 ( 2 ) : 441 - 447.
10Ranganathan S, Salazar H, Benetatos CA, et al. Immunohistochemical analysis of beta - tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy [ J ]. Prostate, 1997,30 (4) : 263 - 268.
3Risch NJ. Searching for genetic determinants in the new millennium [J]. Nature,2000,405:847- 856.
4Weinshilboum R. Inheritance and drug response [J]. N Engl J Med,2003,348:529- 537.
5Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy [J]. Cancer Treat Rev,1998,24:331- 344.
6Rosell R,Lord RV,Taron M,et al. DNA repair and cisplatin resistance in non-small-cell lung cancer [J]. Lung Cancer,2002,38:217- 227.
7Lunn RM,Langlois RG,Hsieh LL,et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency [J]. Cancer Res,1999,59:2557- 2561.
8Schiller JH,Harrington D,Belani CP,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med,2002,346:92- 98.
9Zatloukal P,Petruzelka L,Zemanova M,et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage Ⅲ b and Ⅳ non-small cell lung cancer: a phase Ⅲ randomized trial [J]. Lung Cancer,2003,41:321- 331.
10Xing D,Qi J,Lin D,et al. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population [J]. Int J Cancer,2002,100:600- 605.
7Daniel Reim,Gregor Weirich,Bruno Neu,Monther Bajbouj,Bj?rn L. D. M. Brücher.Synchronous adenocarcinoma of the lung and neuroendocrine carcinoma of the ileum[J]. International Journal of Colorectal Disease . 2008 (3)
8Reed E.ERCCI and clinic al resistance to Platinum-based therapy. Clinical Cancer Research . 2005
9Rosell R,Danenberg KD,Alberola V,et al.Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical Cancer Research . 2004
10Gurubhagavatula S,Liu G,Park S,et al.XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. Journal of Clinical Oncology . 2004
